Health TrialsbyHealthPanel

Double-Expressor Lymphoma

4

Review clinical trials related to Double-Expressor Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

This phase Ib/II trial tests the safety, side effects, best dose and how well giving CX-5461 works for the treatment of patients with B-cell non-Hodgkin lymphoma. CX-5461 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving CX-5461 may be safe, tolerable and/or effective in treating patients with B-cell non-Hodgkin lymphoma.

Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Oct 6, 2026Locations: 8
Eligibility criteria

Patients must have one of the following subtypes of aggressive B-cell non-Hodgki... [+18]

Patients must have recovered from clinically significant adverse events (AEs) of... [+6]

Read more
Status: Not yet recruiting

A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping

Evaluate the efficacy and safety of C Pola R-CHP+X compared to CR-CHOP in the treatment of previously untreated patients with DEL

Participants needed: 156
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Ruijin HospitalUpdated: Apr 6, 2026Locations: 1
Eligibility criteria

1. Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with... [+7]

1. Have previously received systemic or local treatments, including chemotherapy... [+11]

Read more
Status: Recruiting

RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL

This is a prospective, single-arm, multicenter clinical study to evaluate the efficacy and safety of chidamide, rituximab combined with lenalidomide sequential immunochemotherapy in the treatment of newly diagnosed elderly double-expressor diffuse large B-cell lymphoma.

Participants needed: 44
Trial details
Phase: Phase 2Age: 65+Biological sex: AllType: InterventionalSponsor: Zhejiang Cancer HospitalUpdated: Nov 18, 2024Locations: 1
Eligibility criteria

1. Untreated DLBCL patients confirmed by histopathology 2. Immunohistochemistry...

1. The pathological subtypes were PCNSL, PMBCL, EBV-positive DLBCL and HGBL 2. H...

Read more
Status: Not yet recruiting

Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma

This study is trying to explore the mechanism of R-CHOP regimen or tucidinostat plus R-CHOP (CR-CHOP) regimen in the treatment of BCL2/MYC protein double expressor lymphoma.

Participants needed: 400
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Ruijin HospitalUpdated: Oct 22, 2024
Eligibility criteria

Each potential subject must satisfy all of the following criteria to be enrolled...

Any potential subject who meets any of the following criteria will be excluded f...

Read more